This is consistent with previous studies reporting higher rates of colitis and diarrhea with CTLA-4 blockade, likely due to enhanced T-cell activation and reduced regulatory T-cell (Treg) function in the gut mucosa [28,29,30]. Here, CTLA4 is linked to colitis.